2 Cash-Producing Stocks Worth Your Attention and 1 to Ignore
A company that generates cash isn't automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Cash flow is valuable, but it's not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are two cash-producing companies that reinvest wisely to drive long-term success and one that may struggle to keep up.
Trailing 12-Month Free Cash Flow Margin: 22.7%
With roots dating back to the precision balance innovations of Swiss engineer Erhard Mettler, Mettler-Toledo (NYSE:MTD) manufactures precision weighing instruments, analytical equipment, and product inspection systems used in laboratories, industrial settings, and food retail.
Why Are We Cautious About MTD?
Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
Projected sales growth of 3.4% for the next 12 months suggests sluggish demand
Static adjusted operating margin over the last two years shows it couldn't become more efficient
Mettler-Toledo is trading at $1,100 per share, or 25.3x forward P/E. Read our free research report to see why you should think twice about including MTD in your portfolio, it's free.
Trailing 12-Month Free Cash Flow Margin: 20.9%
Started by René Lacerte in 2006 after selling his previous payroll and accounting software company PayCycle to Intuit, Bill.com (NYSE:BILL) is a software as a service platform that aims to make payments and billing processes easier for small and medium-sized businesses.
Why Could BILL Be a Winner?
Winning new contracts that can potentially increase in value as its billings growth has averaged 17.6% over the last year
Prominent and differentiated software culminates in a best-in-class gross margin of 85.1%
Operating margin improvement of 12.7 percentage points over the last year demonstrates its ability to scale efficiently
Bill.com's stock price of $46.99 implies a valuation ratio of 3.1x forward price-to-sales. Is now the time to initiate a position? Find out in our full research report, it's free.
Trailing 12-Month Free Cash Flow Margin: 4.1%
Started as a mail-order tractor parts business, Tractor Supply (NASDAQ:TSCO) is a retailer of general goods such as agricultural supplies, hardware, and pet food for the rural consumer.
Why Are We Positive On TSCO?
Aggressive expansion of new stores reflects an offensive push to quickly grow and sell in markets where it has few or no locations
Forecasted revenue growth of 5.6% for the next 12 months indicates its momentum over the last six years is sustainable
Industry-leading 35.2% return on capital demonstrates management's skill in finding high-return investments
At $50.49 per share, Tractor Supply trades at 23x forward P/E. Is now a good time to buy? See for yourself in our full research report, it's free.
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.
Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
25 minutes ago
- Time Business News
Corrado Garibaldi: The Contrarian Trader Who Profits When Others Panic
In the high-stakes world of Trading Invest Celebrity Italy, where herd mentality often leads to costly mistakes, one investor has built his success on a simple but ruthless principle: When others zig, zag. Corrado Garibaldi—better known in finance circles as Lord Conrad—has carved a reputation as a maverick trader who thrives on going against the grain. His mantra? 'Buy the fear. Sell the euphoria.' The Unconventional Path to Trading Mastery Unlike Wall Street's typical Ivy League-educated financiers, Garibaldi is a self-made trader with no formal finance background. An Italian native, he entered the markets out of necessity, driven by a desire to take control of his financial future. 'I never studied economics or attended business school,' he admits. 'I learned by doing—making mistakes, refining strategies, and realizing that most people lose money because they follow the crowd.' The Contrarian Edge: Why 99.9999% of Traders Are Wrong Garibaldi's core philosophy is rooted in contrarian investing—a strategy that capitalizes on market overreactions. 'When everyone is buying, I'm selling. When panic sets in, I'm buying,' he says. 'The masses are almost always wrong at extremes. That's where the real opportunities lie.' This approach has allowed him to profit from major market swings, whether during the crypto crashes of 2022 or the AI stock frenzy of 2024. Two Sides of the Same Coin: Trader by Day, Investor by Night Garibaldi operates in two distinct modes: As a trader, he's a speed-focused tactician, scalping the Nasdaq and executing swing trades with military precision. As an investor, he's a patient wealth-builder, holding long-term positions in giants like Apple, Microsoft, and Tesla while diversifying into bonds and crypto. His portfolio strategy? 99% long-term holdings, 1% high-octane trading—a balance that maximizes growth while keeping risk in check. The Trader's Mindset: Why Psychology Beats IQ For Garibaldi, trading isn't just about charts—it's about mastering fear and greed. 'Most traders fail because they let emotions drive decisions,' he says. 'The key is to stay mechanical. Follow the plan, not the panic.' He enforces strict rules: ✔ Never risk more than 1% on a single trade ✔ Always use stop-losses ✔ Ignore hype—trade the data, not the narrative 2025 and Beyond: Adapt or Die In an era of AI-driven markets and geopolitical volatility, Garibaldi remains agile—constantly refining strategies and engaging with traders worldwide via social media. 'Markets change. If you're not learning, you're losing,' he warns. Final Word: The Slow Road to Trading Success For aspiring traders, Garibaldi's advice is refreshingly honest: 'This isn't a get-rich-quick game. Consistency beats luck. Small, smart gains compound over time—that's how real wealth is built.' Want to see his strategies in action? Visit Trading Invest Celebrity Italy. TIME BUSINESS NEWS
Yahoo
35 minutes ago
- Yahoo
Virtu Financial Announces Strategic TradeOPS Collaboration, Welcoming First Joint Client
STOCKHOLM and NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NASDAQ: VIRT), a global leader in trading and execution services, and Limina, a leading provider of cloud-native Investment Management Solutions, are proud to announce a strategic collaboration around Virtu's TradeOPS platform. Virtu's TradeOPS is a streamlined, consolidated platform that covers clients' matching, settlements and payment requirements. Designed and built specifically to automate post-trade workflows, including allocation matching and settlements, exception-based processing in TradeOPS is designed to significantly reduce settlement delays, financial penalties, and workload for buyside firms. Combined with Limina's cloud-native Order and Portfolio Management System (O/PMS), this collaboration enables buyside firms to access a fully-integrated, front-to-back workflow—seamlessly and efficiently. The collaboration has welcomed its first joint client, Cliens, who is now benefiting from Virtu's TradeOPS capabilities using DTCC-CTM via Limina's platform. 'We're excited to work with Limina to deliver an integrated and modern workflow for our TradeOPS clients,' said Pegah Esmaeili, Head of Nordic Region at Virtu. 'This integration supports our mission to deliver scalable, outsourced trading solutions by collaborating with innovative local firms like Limina—allowing us to efficiently extend our market-leading products to clients across the region.' Prem Balasubramanian, Head of Virtu's TradeOPS platform highlighted that recent changes in post-trade settlement, such as the shift to T+1 and the migration from SWIFT MT to MX, have introduced new operational challenges for buyside firms. 'By providing streamlined and effective solutions tailored to clients' needs, we can significantly reduce the operational burden and allow firms to refocus on what truly matters: managing investments and driving performance.' Prem also added, 'Working with Limina is a pleasure. The turnaround has been impressively fast, and we're looking forward to continued collaboration ahead.' "This partnership was an obvious choice to further strengthen the integration capabilities of Limina's Order Management System, not only to DTCC CTM but to all venues that tie into Virtu TradeOPS including SWIFT and more," says Kristoffer Fürst, CEO of Limina. 'The integrated solution that Virtu and Limina offer Cliens helps us extend our straight-through process, giving time to more productive tasks which adds value to our customer,' says Martin Öqvist, CEO of Cliens. About Virtu Financial, is a leading financial services firm that leverages cutting-edge technology to provide execution services and data, analytics and connectivity products to its clients and deliver liquidity to the global markets. Leveraging its global market making expertise and infrastructure, Virtu provides a robust product suite including offerings in execution, liquidity sourcing, analytics and broker-neutral, multi-dealer platforms in workflow technology. Virtu's product offerings allow clients to trade on hundreds of venues across 50+ countries and in multiple asset classes, including global equities, ETFs, foreign exchange, futures, fixed income and myriad other commodities. In addition, Virtu's integrated, multi-asset analytics platform provides a range of pre- and post-trade services, data products and compliance tools that clients rely upon to invest, trade and manage risk across global markets. About LiminaLimina's modern Investment Management Platform helps investment managers increase productivity, decrease cost and manage operational risks through a unified platform spanning the entire investment lifecycle. Founded in 2014, and headquartered in Sweden, Limina serves a growing global client base of institutional asset managers, asset owners and hedge funds with our award-winning cloud-native SaaS offering. About CliensCliens is a Swedish active fund manager focusing on delivering long-term high returns. Our funds and discretionary mandates vary from equity to fixed income and investments are made in Swedish all caps as well as Nordic and Global small caps. Contact: Investor Relations and Media RelationsAndrew Smithmedia@ in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025 Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announces that it has performed a strategic review of its current operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets. As a result of this review the Company has informed the Amt für Wirtschaft of Kanton Zürich (Office for Economic Affairs) of its intention to reduce its current workforce by no more than 40 positions, representing a potential of ~24% of all positions. "With strong data emerging from MP0533 and MP0712, our priority is to develop these assets which can provide most value for patients and shareholders. The plan to right-size the organization extends our cash reach into 2028, supporting both the development of our clinical assets and advancement of new products into the pipeline. We recognize the contribution that all of our talented employees have made to Molecular Partners and thank them as we take this difficult decision. The Board and I believe this is the right strategic path for the company to help secure its future success," said Patrick Amstutz, CEO of Molecular Partners. In accordance with Swiss employment law a consultation process with employees has been initiated. Upon completion of the consultation process, the Company will offer affected employees support. This will include, but will not be limited to, severance packages, and support in seeking new employment, coaching or training opportunities. Molecular Partners foresees the full implementation of these changes enacted by the end of 2025 and the reduction of costs to become fully effective early in 2026. As a result of these headcount reductions, the company now anticipates its cash runway to extend into 2028, beyond its prior guidance of 2027. The strategic review was undertaken to identify certain redundancies within the organization, with a focus on research and associated functions. The company will report its half-year financials on August 25, 2025. Molecular Partners maintains its previously announced timelines with clinical data from both MP0533 and MP0712 expected in H2 2025. About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact:Seth Lewis, SVP Investor Relations & StrategyConcord, Massachusetts, +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Tel: +41 44 575 19 35 Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as 'aim', "anticipate', 'expect', 'guidance', 'intend', 'outlook', 'plan', 'potential', 'will' and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
